Latest Conference

An expert discusses the connections between the 2 highly comorbid diseases and some ways to effectively treat both diseases simultaneously.

New positive data for novel ADHD treatment.

An expert discusses recent research evaluating a selective M4 positive allosteric modulator for the treatment of schizophrenia.

Have you registered for the 2023 Annual Psychiatric Times World CME Conference?

Christoph Correll, MD, shares more on paliperidone palmitate 6-month for the treatment of schizophrenia.

Investigators noted sustained improvement in depressive symptoms for up to 6.5 years.

The relationship of this key symptom of major depressive disorder and patient burden is not well understood. These two posters covered it.

“Among employed adults with TRD, esketamine nasal spray treatment was associated with significantly larger improvements in WPL and related costs compared to quetiapine extended-release treatment.”

These 3 posters covered the efficacy and safety of paliperidone palmitate in patients with schizophrenia.

A psychiatry resident from Mexico reflects on the field.

Introspections from an international resident following a US conference shed light on issues in geriatric psychiatry and more.

Did you miss our APA Annual Meeting coverage?

COVID-19 inspired researchers to devise new approaches to clinical trials.

How can trainees build and foster communities?

Poster at annual meeting highlighted the importance of equity, diversity, and inclusion (EDI) training in child and adolescent psychiatry.

Session at annual meeting discussed the importance cultivating diversity.

Mental health professionals should cry. Here's why.

Recognition is the first and most important step to treating behavioral and psychological symptoms of dementia.

From the new Surgeon General’s Advisory on Social Media and Youth Mental Health to our exclusive coverage of the 2023 APA Annual Meeting, here are highlights from the week in Psychiatric Times.

Presenters at the 2023 APA Annual Meeting compared definitions of treatment-resistant depression.

Check out this review of the 2023 APA Annual Meeting presentation on the efficacy and safety of repeat treatment courses using novel medicine, zuranolone.

Psychiatric Times’ very own H. Steven Moffic, MD, spoke about resilience and religion at the 2023 APA Annual Meeting.

Experts discuss findings from a new trial exploring affect-focused psychotherapies for LGBTQ+ patients with PTSD at the 2023 APA Annual Meeting.

Learn more about women’s issues, suicide, and PTSD in the military.

An inside look at what treatments are being discussed in San Francisco...

How can religion impact resilience?

Session at the annual meeting discussed the importance of integrated care electives.

Data presents opportunities to enhance care and improve treatment adherence.

Poster presented at the 2023 American Psychiatric Association Annual Meeting highlights the good and bad of social media information.

Does treatment-resistant depression exist? These 2023 APA Annual Meeting panelists discuss definitions in this exclusive video.